NuvOx Therapeutics
Clinical-stage biopharmaceutical company developing an intravenous perfluorocarbon-based oxygen therapeutic platform to enhance oxygen delivery to blood and tissues. Conducts preclinical studies in multiple animal species and operates Phase I/II/IIb clinical trials in hypoxia-driven indications (stroke, glioblastoma radiosensitization, respiratory distress/ARDS, others). Reports regulatory interactions with MHRA, FDA and Health Canada, maintains on-site clinical manufacturing certifications, and collaborates with academic and government funders.
Industries
Nr. of Employees
small (1-50)
NuvOx Therapeutics
Patents
Compositions of fluorocarbon nanoemulsion, and methods of preparation and use thereof
US-11304899-B2
View Details
Compositions of fluorocarbon nanoemulsion, and methods of preparation and use thereof
US-11304899-B2
View DetailsProducts
Intravenous perfluorocarbon emulsion oxygen therapeutic
A perfluorocarbon emulsion platform formulation for intravenous administration designed to enhance oxygen transfer from lungs to blood and from blood to tissue; under clinical investigation for stroke, glioblastoma radiosensitization, respiratory distress/ARDS, myocardial infarction and other hypoxia-driven indications.
Intravenous perfluorocarbon emulsion oxygen therapeutic
A perfluorocarbon emulsion platform formulation for intravenous administration designed to enhance oxygen transfer from lungs to blood and from blood to tissue; under clinical investigation for stroke, glioblastoma radiosensitization, respiratory distress/ARDS, myocardial infarction and other hypoxia-driven indications.
Services
Design and execution of Phase I/II clinical trials, including randomized, placebo-controlled and dose-escalation studies with imaging and biomarker-driven end-points and DSMB oversight.
Coordination with government agencies and academic collaborators on investigator-led and grant-funded trials and preclinical research programs.
Design and execution of Phase I/II clinical trials, including randomized, placebo-controlled and dose-escalation studies with imaging and biomarker-driven end-points and DSMB oversight.
Coordination with government agencies and academic collaborators on investigator-led and grant-funded trials and preclinical research programs.
Expertise Areas
- Clinical trial management and operations for early- to mid-stage trials
- Perfluorocarbon-based oxygen therapeutic development
- Translational in vivo pharmacology in rodent, rabbit and swine models
- Respiratory failure and ARDS therapeutic development
Key Technologies
- Perfluorocarbon emulsion formulations
- Intravenous nanobubble/microbubble delivery formulations
- Oxygen-sensitive MRI (TOLD MRI)
- PET imaging for tissue hypoxia assessment
News & Updates
Independent Data Safety Monitoring Board recommended the continuation of a multicenter single-blind, randomized, placebo-controlled Phase IIb trial in large vessel occlusion stroke without modification.
U.S. FDA granted Fast Track designation for the intravenous perfluorocarbon oxygen therapeutic for treatment of acute ischemic stroke.
Preliminary Phase Ib respiratory distress results showed dose-dependent improvement in arterial oxygenation with an acceptable safety profile; results presented at the Respiratory Innovation Summit.
Entered into a research collaboration agreement with the U.S. Department of Veteran Affairs to investigate the oxygen therapeutic's ability to improve oxygen delivery in spinal cord injury research.
First patient dosed in the randomized Phase IIb NOVEL trial evaluating the perfluorocarbon emulsion in large vessel occlusion stroke.
MHRA and Research Ethics Committee accepted an amended clinical trial authorization enabling commencement of the Phase IIb NOVEL trial in large vessel occlusion stroke with imaging biomarker end-points.
Independent Data Safety Monitoring Board recommended the continuation of a multicenter single-blind, randomized, placebo-controlled Phase IIb trial in large vessel occlusion stroke without modification.
U.S. FDA granted Fast Track designation for the intravenous perfluorocarbon oxygen therapeutic for treatment of acute ischemic stroke.
Preliminary Phase Ib respiratory distress results showed dose-dependent improvement in arterial oxygenation with an acceptable safety profile; results presented at the Respiratory Innovation Summit.
Entered into a research collaboration agreement with the U.S. Department of Veteran Affairs to investigate the oxygen therapeutic's ability to improve oxygen delivery in spinal cord injury research.
First patient dosed in the randomized Phase IIb NOVEL trial evaluating the perfluorocarbon emulsion in large vessel occlusion stroke.
MHRA and Research Ethics Committee accepted an amended clinical trial authorization enabling commencement of the Phase IIb NOVEL trial in large vessel occlusion stroke with imaging biomarker end-points.